cGAS STING Pathway Market Overview
The cGAS STING pathway market is estimated to be worth $305 million in 2020 and is expected to grow at CAGR of 25% during the forecast period. In recent years, promising insights from research on the cytosolic DNA sensing (cGAS -STING) pathway has caused a lot of enthusiasm within medical science community. Basically, the STING pathway offers an alternative approach to harnessing the immune system, in order to pharmacologically treat a number of clinical conditions, including oncological and autoimmune disorders. The aforementioned therapeutic benefits can be achieved using modulators of the STING / cGAS-pathway. Over the years, a number of such modulators, capable of either activating or downregulating the STING pathway, have been developed. More than 50 experimental interventions based on this relatively novel concept are currently being developed for the treatment of oncological, autoimmune and inflammatory disorders.
The popularity of STING pathway modulation and growing interest of drug developers in this upcoming field of therapeutics is evident in the rising volume of affiliated scientific literature (1,000+ related articles on NCBI’s PubMed portal since 2015). Moreover, capital investments worth over USD 2.6 billion have been made by various private and public sector investors to fund product development activity. In addition, there have been multiple, high value technology licensing deals in cGAS STING pathway market, since 2015. As a result, there has been a considerable rise in number of companies taking initiatives in this field, over the past 4-5 years alone. Interestingly, several big pharma players are also actively evaluating multiple STING agonists / antagonists. It is also worth noting that molecular research into the pathogenesis of the novel SARS-CoV-2 viral strain suggests that COVID-19 may be a STING-related disorder, characterized by delayed over-secretion of IFN-β. STING, in humans, is mostly expressed in lung alveolar epithelial cells, endothelial cells, and spleen cells, which are considered crucial for COVID-19 pathogenesis. Therefore, rapid assessments of STING polymorphisms may actually be useful in identifying individuals who are at high risks of contracting a severe form of this infection. Further, a better understanding of the underlying mechanisms associated with the novel coronavirus induced STING-pathway over-activation, may enable the development of potential therapeutic candidates against COVID-19. Currently, there are no approved STING pathway-targeting drugs / therapy products in the market. However, some promising leads are anticipated to be launched over the coming decade, following which the market is projected to witness a substantial market growth during the forecast period.
Key Companies in cGAS STING Pathway Market
Examples of key companies engaged in cGAS STING pathway market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aduro Biotech, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, ImmuneSensor Therapeutics, Merck, Noxopharm, Spring Bank Pharmaceuticals, Synlogic, Avammune Therapeutics, Curadev, ImmuneSensor Therapeutics, Nimbus Therapeutics, Sirenas, Spring Bank Pharmaceuticals, STINGINN and STipe Therapeutics. This market report includes an easily searchable excel database of all the companies developing agonists or inhibitors of cGAS STING pathway, worldwide.
Recent Developments in STING Pathway Targeting Therapeutics Market:
Several recent developments have taken place in STING pathway targeting therapeutics. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
- In March 2023, MSK researchers identified a key role for the STING signaling pathway in preventing dormant metastatic cancer cells from progressing to active metastases.
Scope of the Report
The “cGAS STING Pathway Market - By Type (Agonist and Antagonist), Molecule (Cyclic Dinucleotides, Non-nucleotides, Live Biotherapeutics, Oncolytic Viruses, Synthetic Peptides and Others), Therapeutic Area (Oncological Disorders, Inflammatory Disorders, Infectious Diseases and Other Diseases), Route of Administration (Intratumoral, Intravenous, Subcutaneous, Oral and Others) and Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2020-2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the cGAS STING pathway market. This market research report focuses specifically on small molecule STING modulators. The market report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in cGAS STING pathway market.
In addition to other elements, the market report includes:
- A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), phase of development (discovery, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first line or greater). The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players). Further the chapter includes an analysis on the clinical trials focused on STING, along with information on parameters, such as recruitment status, study design and clinical endpoints.
- A detailed chapter highlighting various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography).
- Elaborate profiles of key players that are engaged in the development of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, recent developments and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications and current status of development.
- Tabulated profiles of industry players (shortlisted on the basis of the antagonist in pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, key members of the executive team and recent developments), along with descriptions of their respective drug candidates.
- A study on various grants that have been awarded to research institutes engaged in projects related to STING pathway, during the period 2015 - Q1 2020, based on multiple parameters, such as number of grants awarded, amount awarded, funding institute, support period, funding mechanism, type of grant application, grant activity code, most popular NIH department, type of recipient organization, regional distribution, most popular recipient organization(s), prominent project leader(s) and study section. It also includes an analysis of on grant attractiveness.
- An analysis of big pharma players engaged in the development of therapeutics targeting STING pathway, based on several parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area(s), type of therapy and route of administration. In addition, the chapter features a benchmarking analysis of the aforementioned players.
- An analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of therapeutics targeting STING pathway, based on several relevant parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area, funding received, number of investors, type of funding, partnership activity, number of patents filed, grants received, and start-up health indexing.
- A detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of STING modulator, target pathway, therapeutic area, type of publisher, leading players (in terms of number of publications), region, first author organization and key journals (in terms of number of articles published in this domain).
- An analysis of the partnerships that have been established in cGAS STING pathway market, over the period 2015 - Q1 2020, covering research agreements, product / technology licensing agreements, mergers / acquisitions, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals. The chapter highlights analysis based on year of partnerships, type of partnership model, type of STING modulator, therapeutic area, technology platform, most active player(s) (in terms of number of partnerships inked), and region.
- An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies engaged in cGAS STING pathway market. The chapter highlights analysis based on the number of funding instances, amount invested, type of funding, type of STING modulator, therapeutic area, technology platform, most active player(s) (in terms of number of funding instances), most active investor(s) (in terms of number of funding instances) and geographical region.
The key objective of cGAS STING pathway market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for cGAS STING pathway market during the forecast period. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the forecast period 2020-2030. The market research report features likely distribution of the current and forecasted opportunity across [A] type of STING modulator (agonist and antagonist), [B] type of molecule (non-nucleotides, cyclic dinucleotides, live biotherapeutics, oncolytic viruses, synthetic peptides and others) [C] therapeutic area (oncological disorders, inflammatory disorders, infectious diseases and other disorders), [D] route of administration (intratumoral, intravenous, oral, subcutaneous and others), [E] type of technology licensing payment / revenue (upfront payments and milestone payments) and [F] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of market for therapeutics targeting STING pathway and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this market report were influenced by discussions conducted with several stakeholders in cGAS STING pathway market. The market research report features detailed transcripts of interviews held with the following individuals:
- Krzysztof Brzózka (Chris) (Chief Scientific Officer, Ryvu Therapeutics)
- Glen N Barber (Chief Executive Officer, STINGINN)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: What is the cGAS-STING signaling pathway? Answer:
STING / cGAS pathway therapies involve modulation of the STING / cGAS-pathway in order to pharmacologically treat a number of clinical conditions, including oncological and autoimmune disorders.
Question 2: How big is the cGAS STING pathway market? Answer:
The cGAS STING pathway market size is estimated to be worth $305 million in 2020.
Question 3: What is the projected market growth of the cGAS STING pathway market? Answer:
The cGAS STING pathway market is expected to grow at compounded annual growth rate (CAGR) of 25% during the forecast period 2020 – 2030.
Question 4: Who are the leading companies developing modulators of cGAS STING pathway? Answer:
Examples of key companies engaged in cGAS STING pathway market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aduro Biotech, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, ImmuneSensor Therapeutics, Merck, Noxopharm, Spring Bank Pharmaceuticals, Synlogic, Avammune Therapeutics, Curadev, ImmuneSensor Therapeutics, Nimbus Therapeutics, Sirenas, Spring Bank Pharmaceuticals, STINGINN and STipe Therapeutics.
Question 5: How many drug candidates targeting cGAS STING pathway are presently being evaluated under clinical and preclinical stages? Answer:
Presently, over 50 cGAS STING pathway drug candidates are being evaluated under clinical and preclinical stages.
Question 6: How much money has been invested by stakeholders engaged in the cGAS STING pathway market? Answer:
Since 2015, more than USD 2.5 billion has been invested by stakeholders engaged in the cGAS STING pathway market.
Question 7: How many articles related to the cGAS STING pathway have been published over the last few years? Answer:
Since 2015, over 1,000 articles related to the cGAS STING pathway have been published.